📣 VC round data is live. Check it out!
- Public Comps
- Salubris Pharmaceuticals
Salubris Pharmaceuticals Valuation Multiples
Discover Salubris Pharmaceuticals' revenue and EBITDA valuation multiples and investment history, alongside public comparables like Hebei Changshan, Dottikon ES Holding, Beijing Tongrentang, Apellis Pharmaceuticals and more.
Salubris Pharmaceuticals Overview
About Salubris Pharmaceuticals
Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalosporins, and bone resorption inhibitors. Its products mainly focus on the areas of cardio-cerebral vascular disease, diabetes, complications, anti-tumor, and orthopedics. Its business lines include high-end chemical drugs, biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other countries and regions.
Founded
2007
HQ

Employees
3.6K
Website
Financials (LTM)
EV
$5B
Valuation Multiples
Start free trialSalubris Pharmaceuticals Financials
Salubris Pharmaceuticals reported last 12-month revenue of $698M and EBITDA of $172M.
In the same LTM period, Salubris Pharmaceuticals generated $520M in gross profit, $172M in EBITDA, and $108M in net income.
Revenue (LTM)
Salubris Pharmaceuticals P&L
In the most recent fiscal year, Salubris Pharmaceuticals reported revenue of $643M and EBITDA of $171M.
Salubris Pharmaceuticals is profitable as of last fiscal year, with gross margin of 75%, EBITDA margin of 27%, and net margin of 15%.
Financial data powered by Morningstar, Inc.
Salubris Pharmaceuticals Stock Performance
Salubris Pharmaceuticals has current market cap of $5B, and enterprise value of $5B.
Market Cap Evolution
Salubris Pharmaceuticals' stock price is $4.85.
Salubris Pharmaceuticals share price decreased by 1.7% in the last 30 days, and by 29.5% in the last year.
Salubris Pharmaceuticals has an EPS (earnings per share) of $0.09.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5B | $5B | -1.7% | -1.7% | -46.1% | -29.5% | $0.09 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSalubris Pharmaceuticals Valuation Multiples
Salubris Pharmaceuticals trades at 7.5x EV/Revenue multiple, and 30.5x EV/EBITDA.
EV / Revenue (LTM)
Salubris Pharmaceuticals Financial Valuation Multiples
As of June 2, 2026, Salubris Pharmaceuticals has market cap of $5B and EV of $5B.
Salubris Pharmaceuticals has a P/E ratio of 50.2x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Salubris Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Salubris Pharmaceuticals Margins & Growth Rates
Salubris Pharmaceuticals grew revenue by 21% and EBITDA by 1% in the last fiscal year.
In the most recent fiscal year, Salubris Pharmaceuticals reported gross margin of 75%, EBITDA margin of 27%, and net margin of 15%.
Salubris Pharmaceuticals Margins
Salubris Pharmaceuticals Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Salubris Pharmaceuticals Operational KPIs
Salubris Pharmaceuticals' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Salubris Pharmaceuticals' Rule of 40 is 44% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Salubris Pharmaceuticals' Rule of X is 76% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Salubris Pharmaceuticals Competitors
Salubris Pharmaceuticals competitors include Hebei Changshan, Dottikon ES Holding, Beijing Tongrentang, Apellis Pharmaceuticals, Liquidia, CRISPR Therapeutics, CG Oncology, Shanghai RAAS, Scholar Rock and TG Therapeutics.
Most Salubris Pharmaceuticals public comparables operate across Biopharmaceuticals, HealthTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 44.0x | - | (203.9x) | - | |||
| 9.5x | - | 27.1x | - | |||
| 1.6x | 1.6x | 8.7x | 11.0x | |||
| - | 5.7x | - | 1146.0x | |||
| 32.8x | 13.1x | (120.1x) | - | |||
| 1017.8x | 191.8x | (5.8x) | (6.3x) | |||
| 1029.0x | 595.7x | (22.0x) | (18.4x) | |||
| 5.1x | - | 17.1x | - | |||
This data is available for Pro users. Sign up to see all Salubris Pharmaceuticals competitors and their valuation data. Start Free Trial | ||||||
Investments by Salubris Pharmaceuticals
Salubris Pharmaceuticals has invested in 7 companies to date.
Latest investment by Salubris Pharmaceuticals was on December 9th 2025. Salubris Pharmaceuticals invested in Precision Scientific in their $14M Undisclosed stage round (EV/Revenue multiple available to Pro users).
Latest Investments by Salubris Pharmaceuticals
| Description | Precision Scientific is a research service provider for pharmaceuticals and biotech using AI technology ALBERT for oncology analysis. Based in South Korea, it processes multi-omics data to identify drug targets, biomarkers, indications, resistance mechanisms, and combination therapies. | - | Precision Scientific is a research service provider for pharmaceuticals and biotech using AI technology ALBERT for oncology analysis. Based in South Korea, it processes multi-omics data to identify drug targets, biomarkers, indications, resistance mechanisms, and combination therapies. | - | |
| HQ Country | |||||
| HQ City | Beijing | - | Beijing | - | |
| Deal Date | 9 Dec 2025 | 22 Apr 2024 | 26 Jun 2023 | 28 Mar 2023 | |
| Round | Undisclosed stage | Series A | Series A | Strategic investment | |
| Raised | $14M | $35M | $14M | $35M | |
| Investors | Guangxi Investment Capital Management; Jingu Huifeng; Juyi Investment; Shenghong Zhongheng Fund; Salubris Pharmaceuticals | Salubris Pharmaceuticals | ShenZhen GTJA Investment Group; Salubris Pharmaceuticals | Salubris Pharmaceuticals | |
| Valuation | undisclosed | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Salubris Pharmaceuticals investments and their VC round multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Salubris Pharmaceuticals
| When was Salubris Pharmaceuticals founded? | Salubris Pharmaceuticals was founded in 2007. |
| Where is Salubris Pharmaceuticals headquartered? | Salubris Pharmaceuticals is headquartered in China. |
| How many employees does Salubris Pharmaceuticals have? | As of today, Salubris Pharmaceuticals has over 3K employees. |
| Is Salubris Pharmaceuticals publicly listed? | Yes, Salubris Pharmaceuticals is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Salubris Pharmaceuticals? | Salubris Pharmaceuticals trades under 002294 ticker. |
| When did Salubris Pharmaceuticals go public? | Salubris Pharmaceuticals went public in 2009. |
| Who are competitors of Salubris Pharmaceuticals? | Salubris Pharmaceuticals main competitors include Hebei Changshan, Dottikon ES Holding, Beijing Tongrentang, Apellis Pharmaceuticals, Liquidia, CRISPR Therapeutics, CG Oncology, Shanghai RAAS, Scholar Rock, TG Therapeutics. |
| What is the current market cap of Salubris Pharmaceuticals? | Salubris Pharmaceuticals' current market cap is $5B. |
| What is the current revenue of Salubris Pharmaceuticals? | Salubris Pharmaceuticals' last 12 months revenue is $698M. |
| What is the current revenue growth of Salubris Pharmaceuticals? | Salubris Pharmaceuticals revenue growth (NTM/LTM) is 22%. |
| What is the current EV/Revenue multiple of Salubris Pharmaceuticals? | Current revenue multiple of Salubris Pharmaceuticals is 7.5x. |
| What is the current EBITDA of Salubris Pharmaceuticals? | Salubris Pharmaceuticals' last 12 months EBITDA is $172M. |
| What is Salubris Pharmaceuticals' EBITDA margin? | Salubris Pharmaceuticals' last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of Salubris Pharmaceuticals? | Current EBITDA multiple of Salubris Pharmaceuticals is 30.5x. |
| How many companies Salubris Pharmaceuticals has acquired to date? | Salubris Pharmaceuticals hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Salubris Pharmaceuticals has invested to date? | As of June 2026, Salubris Pharmaceuticals has invested in 7 companies. |
| What was the last Salubris Pharmaceuticals investment? | On 9th December 2025 Salubris Pharmaceuticals invested in Precision Scientific, participating in a $14M Undisclosed stage round, alongside Guangxi Investment Capital Management, Jingu Huifeng, Juyi Investment, and Shenghong Zhongheng Fund. |
| In what companies Salubris Pharmaceuticals invested in? | Salubris Pharmaceuticals invested in SalubrisBio, KingstronBio, Precision Scientific, Mercator MedSystems, Viracta Therapeutics, GO Therapeutics, and Zhongke Jiankang Wang. |
See public comps similar to Salubris Pharmaceuticals
Lists including Salubris Pharmaceuticals
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

